Q-omics provides the consensus-scored TUBGCP2 profile across patient tissues and cancer cell-line models. TUBGCP2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TUBGCP2 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, TUBGCP2 protein abundance shows 20,838 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, THCA, and GBM as cancer lineages where TUBGCP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBGCP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBGCP2 survival associations across molecular data types. TUBGCP2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBGCP2 RNA expression–survival associations across cancer types. High TUBGCP2 expression shows unfavorable associations in ACC, COAD and READ, but favorable associations in LGG, KIRP and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TUBGCP2 RNA expression.
This table summarizes TUBGCP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 11. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TUBGCP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBGCP2 shows lower tumor expression in THCA, KICH and KIRP and higher tumor expression in LIHC, COAD and HNSC. The THCA box plot shows higher TUBGCP2 RNA expression in normal versus tumor tissue (log2 FC = −0.378, t-test p < 0.001).
This table shows molecular features associated with TUBGCP2 in patient tissues and cancer cell lines. In patient samples, TUBGCP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TUBGCP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
